← Back to guidelines
Oncology13 papers

Bronchiolo-alveolar adenocarcinoma

Last edited: 4/15/2026

Overview

Bronchiolo-alveolar adenocarcinoma (BAC) is a subtype of lung adenocarcinoma characterized by its distinctive growth pattern along the alveolar septa and terminal bronchioles. It often presents with indolent behavior but can exhibit variable aggressiveness 1.

Diagnosis

  • Histopathological Confirmation: Open lung biopsy essential for definitive diagnosis 1.
  • Immunohistochemistry: Useful for confirming endothelial origin or specific markers 1.
  • Imaging: CT scans may show characteristic patterns but are not definitive; biopsy remains crucial 1.
  • Management

  • Surgical Resection: Primary treatment for localized disease 1.
  • Observation: For asymptomatic cases with low progression tendency, close monitoring may be appropriate 1.
  • Systemic Therapy: Specific drug classes and doses not detailed in current abstracts 1.
  • Special Populations

  • No Specific Data: Abstracts do not provide information on management in pregnancy, pediatrics, elderly, or comorbid conditions 1.
  • Key Recommendations

  • Definitive Diagnosis Requires Histopathological Examination: Open lung biopsy is essential for diagnosing intravascular bronchioloalveolar tumour (IVBAT) 1 (Evidence: Strong).
  • Monitoring Suited for Asymptomatic, Slowly Progressing Cases: Close observation may be sufficient for patients with presumed long-duration, minimally progressive disease 1 (Evidence: Moderate).
  • Surgical Intervention for Localized Disease: Surgical resection should be considered the first-line treatment for localized BAC 1 (Evidence: Expert opinion).
  • References

    1 De-Luca S, Sanguinetti CM, Bearzi I, Murer B. Intravascular bronchioloalveolar tumour. The European respiratory journal 1990. link

    Original source

    1. [1]
      Intravascular bronchioloalveolar tumour.De-Luca S, Sanguinetti CM, Bearzi I, Murer B The European respiratory journal (1990)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG